Michael Burry's Top 5 Stock Holdings

In partnership with

Feeling Off Lately? Try One Week of Therapy, Free

Life can be overwhelming, but getting support shouldn’t be. This May for Mental Health Awareness Month, BetterHelp is offering one week of therapy completely free, so you can experience what real support feels like—no cost, no pressure.

You’ll be matched with a licensed therapist in as little as 24 hours, and connect on your schedule—by phone, video, or chat. With 35,000+ professionals, there’s someone for you. 94% of BetterHelp users report feeling better after starting therapy, and now you can try it yourself, risk-free.

Start Your Free Week

Let’s face it: when your portfolio is more rollercoaster than rocket ship, or your boss just dropped another “urgent” email at 6:59 PM, stress can hit harder than a market correction. That’s where BetterHelp steps in-think of it as your emotional stop-loss order. With BetterHelp, you get matched with a licensed therapist (no commute, no waiting room anxiety) and can chat by text, phone, or video, even after market hours. So whether you’re sweating over your next big trade or just need to vent about workplace drama, you’ve got a pro in your corner-on your schedule, not theirs.

No need to “tough it out” like a cowboy with a snakebite or a trader riding out a red day. BetterHelp is designed for real life-where you can swap therapists if the fit isn’t right, message your counselor 24/7, and get practical tips for setting boundaries, managing stress, and keeping your cool when the Dow drops (again). Over two million people have already found relief with BetterHelp, so why not you? Because sometimes, the smartest investment you can make is in your own peace of mind.

Top 5 Stocks Michael Burry Is Buying Right Now

Michael Burry, famed for his contrarian investment strategies and prescient calls, continues to make headlines with his latest portfolio moves. As of Q4 2024 and into early 2025, Burry’s Scion Asset Management has recalibrated its holdings, balancing between defensive sectors like healthcare and high-conviction plays in Chinese tech and consumer stocks. Below, we profile the top five stocks Burry is buying or holding in significant size, with a special focus on Molina Healthcare.

1. Alibaba Group Holding Ltd. (BABA)

• Portfolio Weight: ~16.4%

• Position: 150,000 shares (trimmed by 25% last quarter)

• Performance: Up over 50% from reported prices as of May 2025

Alibaba remains Burry’s largest holding despite a recent reduction in position size. The Chinese e-commerce giant has rebounded sharply, outperforming the S&P 500 and benefiting from renewed investor optimism and strong earnings. Burry’s partial trim suggests prudent risk management amid ongoing regulatory uncertainty, but his continued conviction signals belief in Alibaba’s long-term value and recovery potential134.

2. Baidu Inc. (BIDU)

• Portfolio Weight: ~13.6%

• Position: 125,000 shares (unchanged last quarter)

• Performance: Up about 8% since reported prices

Baidu, often dubbed the “Google of China,” is another core holding. Burry has not changed his position, signaling confidence in Baidu’s transition to an AI-first company and its resilience amid China’s economic and regulatory headwinds. The stock’s recent gains reflect both company-specific progress and broader optimism around Chinese tech134.

3. JD.com Inc. (JD)

• Portfolio Weight: ~13.4%

• Position: 300,000 shares (trimmed by 40% last quarter)

• Performance: Relatively flat, with minor declines in 2025

JD.com, a major Chinese e-commerce player, remains a top-three holding despite a significant reduction. Burry’s move to cut back may reflect caution over Chinese equity volatility, but his remaining stake underscores ongoing belief in JD’s operational strength and potential upside from government stimulus and discounting strategies13.

4. Molina Healthcare Inc. (MOH)

• Portfolio Weight: ~9.4%

• Position: 25,000 shares (trimmed by ~17% last quarter)

• Performance: Up about 8–10% from reported prices in early 2025

Molina Healthcare is Burry’s leading U.S. healthcare bet, specializing in Medicaid, Medicare, and Marketplace programs. Despite trimming his position, Burry retains a sizable stake, likely viewing Molina as a defensive play amid economic uncertainty. The company’s recent results show steady revenue and income growth, though membership has declined slightly. Molina’s ongoing expansion-highlighted by the acquisition of ConnectiCare and new state contracts-positions it for continued growth. Analysts remain bullish, with price targets around $340–$3561234.

5. PDD Holdings Inc. (PDD)

• Portfolio Weight: ~9.4%

• Position: 75,000 shares (new position)

• Performance: Up about 7–15% since reported prices

PDD Holdings, the parent of Pinduoduo, is Burry’s latest foray into Chinese e-commerce. This new position reflects a bet on China’s consumer recovery and PDD’s innovative discount-driven model. Despite ongoing U.S.-China trade tensions, Burry appears to see value in PDD’s growth trajectory and potential upside from economic stimulus134.

Portfolio Strategy and Outlook

Burry’s current portfolio showcases a blend of caution and conviction:

• Defensive Healthcare: Molina Healthcare and HCA Healthcare provide stability and hedge against market volatility, reflecting Burry’s preference for demand-driven, recession-resilient businesses.

• Chinese Tech Rebalancing: While trimming exposure to some Chinese giants, Burry maintains significant stakes in Alibaba, Baidu, JD.com, and adds PDD, signaling selective optimism in the sector.

• Consumer and Specialty Plays: New positions in Estee Lauder and continued bets on niche companies like Bruker and Magnera round out the portfolio, capturing potential rebounds in discretionary and specialized markets.

Burry’s approach in 2025 highlights his willingness to pivot quickly, balancing risk management with targeted growth opportunities. His continued focus on healthcare and Chinese tech demonstrates a nuanced understanding of global market dynamics and a commitment to value-driven investing134.

Summary Table: Michael Burry’s Top 5 Holdings (Q4 2024–May 2025)

Burry’s portfolio in early 2025 reflects a careful balance between defensive U.S. healthcare and high-upside Chinese tech, with Molina Healthcare standing out as a core holding for its stability and growth prospects1234.

If you’re curious about what’s catching Michael Burry’s eye in 2025, you’re not alone. His latest stock picks-spanning Chinese tech giants and U.S. healthcare-showcase his signature mix of deep value hunting and contrarian thinking. Let’s break down what’s really going on with these five names and what their recent performance might mean for investors looking to understand Burry’s logic.

First up, Burry’s continued interest in Chinese tech stocks like Alibaba, Baidu, JD.com, and PDD Holdings is a bold move. These companies have seen a rollercoaster of regulatory pressure and economic uncertainty, but Burry appears to be betting that the worst is behind them. Alibaba, for example, has rebounded over 50% recently, and Baidu and PDD have also posted solid gains. JD.com, on the other hand, has lagged a bit, but Burry’s partial trimming of this position suggests he’s not afraid to lock in profits or reduce risk when the outlook gets murky. This approach fits his reputation for going against the grain-he’s willing to hold unpopular stocks if he sees long-term value, but he’s also quick to adjust when the story changes3.

On the U.S. side, Molina Healthcare stands out as a stabilizing force in Burry’s portfolio. Healthcare, especially companies with a focus on Medicaid and Medicare like Molina, tends to be less volatile when the broader market gets choppy. Molina’s recent growth has been steady, even as membership numbers have dipped slightly, and Burry’s choice to trim (rather than exit) his position shows he still sees it as a solid defensive play. This kind of balance-pairing high-upside international tech bets with reliable U.S. healthcare-is classic Burry, aiming for both growth and downside protection3.

What’s also interesting is how Burry manages his risk. He doesn’t spread himself thin across dozens of stocks; instead, he carefully sizes each position, diversifies across sectors, and isn’t afraid to take contrarian stances. His recent moves-cutting back on some Chinese tech, adding new names in healthcare and consumer brands, and even making selective bets in insurance and specialty industries-reflect a hands-on, research-driven approach. He’s not chasing trends; he’s looking for companies with strong fundamentals, good management, and the potential to weather whatever the market throws at them

Our analysis of Burry’s Portfolio

Michael Burry's Q4 2024 portfolio reveals a laser focus on contrarian bets and undervalued sectors. Let’s break down the key factors shaping these investments:

External Factors

China’s Regulatory & Trade Landscape
Burry’s heavy weighting in Chinese tech (52% of his portfolio)13 faces headwinds from U.S.-China trade tensions and potential Trump-era tariffs1. However, recent Chinese stimulus measures and discounted valuations (Alibaba trades at 8x forward earnings vs. Amazon’s 40x)4 create asymmetric upside opportunities.

Consumer Behavior Shifts

• E-commerce: JD.com’s 16% revenue growth in Q1 20255 reflects China’s resilient online shopping demand despite economic slowdowns.

• Luxury Sector Slump: Estée Lauder’s 49% stock decline13 aligns with weakening global demand for high-end cosmetics post-pandemic.

Healthcare Policy
Molina Healthcare ($MOH) and HCA Healthcare ($HCA) benefit from aging populations and stable Medicaid/Medicare funding1, serving as defensive hedges.

Business Metrics

Significant Trends

1. Burry’s China Pivot: Trimmed $BABA and $JD stakes13 but added $PDD, signaling selective confidence in China’s e-commerce resilience.

2. Healthcare Hedge: 15.2% portfolio allocation to $MOH/$HCA1 mirrors institutional moves toward recession-resistant sectors.

3. Luxury Sector Bottom-Fishing: Estée Lauder’s addition23 suggests Burry anticipates a consumer rebound post-restructuring.

Business Initiatives

• Alibaba: Doubling down on AI/cloud infrastructure ($2B commitment)16 to diversify beyond core e-commerce.

• JD.com: Aggressive discounting strategy + logistics automation to counter Pinduoduo’s growth15.

• Estée Lauder: Cutting 3,000 jobs and streamlining brands to save $1.5B annually23.

• Baidu: Shifting from search to AI services (autonomous driving, Ernie chatbot)14.

Forward-Looking Statements

• Alibaba’s Leadership: “We’re entering a new phase of innovation-driven growth”6, targeting $100B annual cloud revenue by 20274.

• JD.com’s Guidance: Projects 12-15% annual revenue growth through 2026 via supply chain tech upgrades5.

• Burry’s Macro View: Implicitly bets on Chinese tech’s long-term recovery (“growth potential outweighs geopolitical risks”)4, while using healthcare stocks as ballast against volatility.

Objective Analysis

Burry’s portfolio screams calculated contrarianism. While his China bets carry regulatory risks, the valuations (e.g., Alibaba at 0.3x price-to-sales4) and corporate turnaround efforts (Estée Lauder’s restructuring) align with his value-investing DNA. However, the lack of U.S. tech exposure leaves him vulnerable if China’s stimulus underwhelms.

Key question: Is this a genius pivot or a repeat of his 2021 “dead cat bounce” misstep? The 2025 earnings trajectory for $BABA (6.4% YoY revenue growth)6 vs. $JD’s 16% surge5 suggests bifurcated outcomes. Proceed with cautious optimism

In summary, Burry’s top five stocks right now tell a story of strategic balance: bold bets on a Chinese tech rebound, tempered by the safety net of U.S. healthcare. Whether or not you agree with his picks, there’s no denying the depth of analysis and conviction behind each move.

Disclaimer: This content is for informational purposes only and does not constitute financial advice. Always do your own research or consult a professional before making investment decisions.